

RESULTS UPDATE

12 February 2025
Sweden
Capital Goods

Research analysts:

Markus Almerud

Svedbergs Group

Share price: SEK44.9

Fair value range: SEK51.0–70.0

We expect the recovery to continue in 2025 – Q4 review

Growth trend continued to recover...

Organic growth was positive in Q4 for the first time since Q3(22). According to the company there are no tangible signs of a recovery, but we expect continued improvement throughout 2025 as the general economy recovers. Sweden and Finland remain the most difficult markets with the projects markets still lacklustre.

...and the EBIT margin target of 15% was reached in Q4

Roper Rhodes continued to grow sales and expand its margin in a difficult market, which is important since it accounts for almost half the group. With the gross margin expanding 160bps the EBITA margin met the margin target level of 15% in the quarter. We believe that the largest margin potential for the group, and what is required to reach 15% margin sustainably, is the Svedbergs brand margin recovering to historical levels. According to the company, the productivity in its production unit improved towards the end of the quarter and it believes the Svedbergs brand can reach double-digit margins also without a volume recovery. This is not reflected in our estimates.

Well prepared for an upturn in the market

The company has used the downturn to work on its cost base and we believe a turn in the market would have a significant impact on earnings. We still believe that the Svedbergs brand is able to return to double-digit margins even without a turn in market. Even though we see the timing of a recovery as uncertain, we believe we are in the trough and it will not get worse.

Limited estimate changes

We make low single-digit changes to our adj. EPS estimates on slight changes in net financials and tax forecasts and revise our fair value range to SEK51–70 (SEK52–70).

Upcoming events

- AGM 2025: 29 Apr 2025
- Q1 Report: 29 Apr 2025
- Q2 Report: 18 Jul 2025
- Q3 Report: 29 Oct 2025

Changes in this report			
	From	To	Chg
EPS adj. 2025e	4.2	4.1	-3%
EPS adj. 2026e	4.7	4.5	-2%
EPS adj. 2027e	5.1	4.9	-3%

Key facts	
No. shares (m)	53.0
Market cap. (USDm)	219
Market cap. (SEKm)	2,379
Net IB Debt. (SEKm)	628
Adjustments (SEKm)	0
EV (2025e) (SEKm)	3,007
Free float	55.9%
Avg. daily vol. ('000)	22
Risk	High Risk
Fiscal year end	December
Share price as of (CET)	11 Feb 2025 00:00

Key figures (SEK)		2024	2025e	2026e	2027e
Sales (m)		2,184	2,265	2,354	2,449
EBITA (m)		312	338	363	385
EBITA adj. (m)		312	338	363	385
EPS		3.25	3.79	4.25	4.66
EPS adj.		3.56	4.08	4.55	4.95
DPS		1.50	1.75	2.00	2.33
Sales growth Y/Y		20%	4%	4%	4%
EPS adj. growth Y/Y		-13%	15%	11%	9%
EBITA adj. margin		14.3%	14.9%	15.4%	15.7%
EV/Sales		1.4	1.3	1.2	1.1
EV/EBITA adj.		9.4	8.9	7.9	7.2
EV/EBITA		9.4	8.9	7.9	7.2
EV/EBIT		9.9	9.3	8.3	7.5
P/E adj.		12.6	11.0	9.9	9.1
P/BV		1.6	1.5	1.4	1.3
Dividend yield		3.3%	3.9%	4.5%	5.2%
FCF yield		4.4%	8.6%	9.6%	10.5%
ROCE		12.0%	12.1%	13.2%	14.0%
ROE adj.		14.7%	13.7%	14.2%	14.4%
Net IB debt/EBITDA		2.0	1.6	1.2	0.8

Share price - 5Y

Svedbergs Group
OMX Stockholm_PI (Se) (Rebased)

High/Low (12M)		SEK50.9/34.8		
Perf.	3M	6M	12M	YTD
Abs.	-4.0	-1.4	22.3	8.3
Rel.	-7.8	-9.2	7.1	0.7

This report has been commissioned and sponsored by Svedbergs Group. Commissioned research is considered to be marketing communication (i.e. not investment research under MiFID II). This material may be subject to restrictions on distribution in certain areas. For more information, see disclosures and disclaimers at the end of this report

Equity story

Near term:
6–12m

We believe we are in the trough of the housing construction market, both when it comes to newbuilds and renovations. The timing, as well as the strength, of the recovery is uncertain. Our best estimate is that we will see a gradual recovery in 2025.

Long term:
5Y+

The shortage of housing should drive growth in bathroom installations over time. We would expect mid-single digit market growth over time.

Key risks:

- The housing market does not recover
- The economic downcycle is prolonged
- The Svedbergs brand is not able to recover its margin to historical levels
- Acquisitions develop worse than expected
- It is not able to find suitable targets

Company description

Svedbergs Group designs and manufactures bathroom interiors and sanitary articles. The company offers a comprehensive range of bathroom products, including furniture, washbasins, mixers, showers, heated towel rails, and WCs among others. The company operates through the subsidiaries Svedbergs, Macro Design, Cassoe, Roper Rhodes and Thebalux. Its strategy is to grow by acquiring independent innovative and sustainable brands that complement the group's geographic presence or portfolio.

Key industry drivers

- Housing renovations
- New housing construction

Industry outlook

- We believe that the construction market, both new and renovation has troughed
- We expect a slow recovery in coming years

Largest shareholders

Stena	43.0%
Nordea Funds	14.2%
If Skadeförsäkring	11.5%

Cyclicality

Cyclicality: Yes
Late


Key peers

FM Mattsson, Ifö, Gustavsberg, Inwido, Balco Group, Nordic Waterproofing

Valuation and methodology


Our fair value range is based on upside and downside scenarios applied to multiples-based valuations. We use a P/E of 13x and an EV/EBITA of 11x, to which we apply our 2026 estimates and discount the values back to today. Peers are trading at average P/E(26e) of 11x and EV/EBITA(26e) of 11x. Given Svedberg's solid balance sheet we believe it is fair that it trades at higher P/E than EV/EBITA.

Fair value range 12m




Our downside scenario is based on 3-year sales CAGR of 4% and EBITA CAGR of 8%; while our upside scenario is based on 3-year sales CAGR of 6% and EBITA CAGR of 16%.


Key metrics



PE 12m forward



Long term valuation trend




Source: Carnegie Research & company data

Svedbergs Group in key charts

Svedbergs Group sales (SEKbn)


The acquisitions of Roper Rhodes in the UK and Thebalux in the Netherlands have driven sales of the group...



Source: Company data, Carnegie Research

Svedbergs Group geographical sales split (2024)


... and now Sweden accounts for less than a fifth of sales compared to around 70% in 2021



Source: Company data, Carnegie Research

Svedbergs Group organic growth


We expect the organic growth trend to continue to improve



Source: Company data, Carnegie Research

As the margin in Svedbergs (brand) part of the group recovers, the group margin will recover

Svedbergs Group sales and EBITA margin



Source: Company data, Carnegie Research

Valuation and risks

Our fair value range is based on upside and downside scenarios applied to multiples-based valuations. Based on our estimates, we arrive at a fair value range of SEK51–70 (previously SEK52–70).

Assumptions


Our multiples-based approach returns values of SEK51–70 per share. We use a P/E of 13x and an EV/EBITA of 11x, to which we apply our 2026 estimates and discount the values back to today. Peers are trading at average 2026e P/E of 11x and 2026e EV/EBITs of 11x. Given Svedberg's solid balance sheet we believe it is fair that it trades at higher P/E than EV/EBIT.

Our downside scenario is based on 3-year sales CAGR of 4% and EBITA CAGR of 8% while our upside scenario is based on 3-year sales CAGR of 6% and EBITA CAGR of 16%.

Multiple-based calculations	Downside	Upside
<u>P/E based</u>		
2026 EPS (SEK)	4.3	5.4
P/E	13x	13x
Value end of 2025 (SEK)	55	70
PV per share (SEK)	51	65
<u>EV/EBITA based</u>		
2026 EBITA (SEKm)	363	447
EV/EBITA	11x	11x
EV end of 2025 (SEKbn)	4.0	4.9
Current EV (SEKbn)	3.7	4.5
Current net debt (SEKbn)	0.8	0.8
Equity value (SEKbn)	2.9	3.7
No shares (m)	53	53
Value per share (SEK)	54	70


Source: Carnegie Research

Svedbergs peer group P/E 2026e



Source: Factset, Carnegie Research

Svedbergs peer group EV/EBIT 2026e



Source: Factset, Carnegie Research

Risks

Svedbergs faces several potential risks that could impact its operations and financial performance. Below we have outlined the risks that we consider to be the most significant for the company. Note that the list should not be considered exhaustive and is presented in no particular order.

- **Market and economic risks:** Demand for Svedberg's products depends on the broader economic climate, including interest rates, exchange rates, and unemployment rates. Economic slowdowns can reduce consumer spending on home improvements, directly impacting demand for bathroom products. Declines in housing transactions and new constructions can adversely affect sales, as fewer new bathrooms are installed.
- **Operational risks:** Dependence on suppliers for raw materials and finished products makes the company vulnerable to supply chain interruptions, which can affect production schedules and costs. As the Group's growth strategy includes acquisitions, such as Thebalux, there is a risk that the acquired units will not perform as expected.
- **Strategic risks:** While M&A can drive growth, they also carry risks like overvaluation, integration difficulties, and diversion of management attention. Maintaining a premium brand image requires continuous innovation and quality assurance. Failure to do so could erode market share.
- **Regulatory and compliance risks:** The company must comply with environmental laws concerning production processes, waste management, and product materials. Non-compliance can lead to fines and reputational damage. Ensuring all products meet safety and quality standards is crucial. Any lapses can result in recalls and legal issues.
- **Technological risks:** The need to adopt new technologies for production, distribution, and customer engagement requires significant investment. Lagging in this area can lead to competitive disadvantages. As operations become more digitized, the risk of cyber-attacks increases, potentially compromising sensitive data and disrupting business activities.

Interim figures

	2025e			2026e			2027e		
Svedbergs - Estimate changes	Old	New	Chg	Old	New	Chg	Old	New	Chg
Sales	2,283	2,265	-1%	2,373	2,354	-1%	2,469	2,449	-1%
Growth	4%	4%	-51 bps	4%	4%	-0 bps	4%	4%	-1 bps
Organic	3%	2%	-52 bps	4%	4%	-0 bps	4%	4%	-1 bps
Acq/div	0%	0%	+0 bps	0%	0%	+0 bps	0%	0%	+0 bps
Currency	1%	1%	+0 bps	0%	0%	+0 bps	0%	0%	+0 bps
Adj EBITA	331	338	2%	357	363	2%	379	385	2%
Adj EBITA margin	14.5%	14.9%	+42 bps	15.0%	15.4%	+40 bps	15.4%	15.7%	+38 bps
PPA	-16	-16	1%	-16	-16	1%	-16	-16	1%
EO	0	0	n.m	0	0	n.m	0	0	n.m
EBIT	331	338	2%	357	363	2%	379	385	2%
EBIT margin	14.5%	14.9%	+42 bps	15.0%	15.4%	+40 bps	15.4%	15.7%	+38 bps
Pre-tax profit	280	271	-3%	313	304	-3%	343	333	-3%
Net profit	207	201	-3%	231	225	-3%	254	247	-3%
EPS	3.9	3.8	-3%	4.4	4.3	-3%	4.8	4.7	-3%
EPS adj	4.2	4.1	-3%	4.7	4.5	-2%	5.1	4.9	-3%
Sales									
Svedbergs	410	401	-2%	430	420	-2%	452	441	-2%
Macro Design	174	172	-1%	181	179	-1%	188	186	-1%
Cassoe	92	87	-6%	95	90	-6%	98	93	-6%
Roper Rhodes	1,184	1,193	1%	1,227	1,236	1%	1,271	1,280	1%
Thebalux	423	413	-2%	440	430	-2%	460	449	-2%
Group	2,283	2,265	-1%	2,373	2,354	-1%	2,469	2,449	-1%
Adj. EBITA									
Svedbergs	17	19	10%	23	24	7%	29	31	5%
Macro Design	16	18	7%	18	19	6%	19	20	6%
Cassoe	18	17	-9%	19	17	-9%	19	18	-9%
Roper Rhodes	223	233	4%	236	246	4%	245	255	4%
Thebalux	96	93	-4%	102	98	-4%	106	102	-4%
Corporate	-40	-40	0%	-40	-40	0%	-40	-40	0%
Group	331	338	2%	357	363	2%	379	385	2%
Adj. EBITA margin									
Svedbergs	4.1%	4.6%	+52 bps	5.3%	5.8%	+49 bps	6.5%	7.0%	+47 bps
Macro Design	9.4%	10.2%	+78 bps	9.8%	10.6%	+75 bps	10.2%	11.0%	+72 bps
Cassoe	19.7%	19.0%	-65 bps	19.7%	19.1%	-63 bps	19.7%	19.1%	-61 bps
Roper Rhodes	18.8%	19.5%	+67 bps	19.2%	19.9%	+65 bps	19.3%	19.9%	+63 bps
Thebalux	22.8%	22.4%	-39 bps	23.1%	22.7%	-38 bps	23.2%	22.8%	-36 bps
Group	14.5%	14.9%	+42 bps	15.0%	15.4%	+40 bps	15.4%	15.7%	+38 bps

Source: Carnegie Research

Interim figures

Carnegie estimates	2023	2024	2025														
SEKm	Q4	Q1	Q2	Q3	Q4	Q1e	Q2e	Q3e	Q4e		2023	2024	2025e	2026e	2027e		
Sales	460	572	562	512	537	592	583	535	556		1,824	2,184	2,265	2,354	2,449		
Growth	5%	20%	23%	19%	17%	4%	4%	4%	4%		0%	20%	4%	4%	4%		
Organic	-5%	-4%	-2%	-1%	0%	1%	2%	3%	4%		-6%	-2%	2%	4%	4%		
Currency	3%	2%	2%	-2%	2%	3%	1%	1%	0%		4%	1%	1%	0%	0%		
Acquisitions	7%	22%	23%	22%	14%	0%	0%	0%	0%		2%	20%	0%	0%	0%		
Adj EBITA	59	84	76	71	81	89	86	80	83		240	312	338	363	385		
Adj EBITA margin	12.9%	14.6%	13.5%	13.9%	15.1%	15.0%	14.7%	15.0%	14.9%		13.2%	14.3%	14.9%	15.4%	15.7%		
PPA	-3	-4	-4	-4	-4	-4	-4	-4	-4		-11	-16	-16	-16	-16		
EO	-15	0	0	0	0	0	0	0	0		-18	0	0	0	0		
EBIT	41	80	72	67	77	85	82	76	79		211	296	322	348	370		
EBIT margin	9.0%	13.9%	12.8%	13.2%	14.4%	14.4%	14.0%	14.3%	14.2%		12%	14%	14%	15%	15%		
Net financials	-18	-12	-18	-30	-7	-11	-11	-11	-18		-51	-67	-51	-43	-37		
Pre-tax Profit	23	67	54	38	71	74	71	65	61		160	229	271	304	333		
Tax	-13	-17	-13	-10	-21	-19	-18	-17	-16		-41	-61	-70	-79	-87		
Tax rate	58%	25%	24%	26%	30%	26%	26%	26%	27%		26%	27%	26%	26%	26%		
Net profit	10	50	40	28	50	55	52	48	45		119	168	201	225	247		
EPS (SEK)	0.28	0.95	0.76	0.53	0.93	1.03	0.99	0.91	0.84		3.4	3.3	3.8	4.3	4.7		
EPS Adj (SEK)	0.54	1.02	0.84	0.60	1.01	1.11	1.06	0.98	0.93		4.1	3.6	4.1	4.5	4.9		
Sales	2024					2025											
SEKm	Q4	Q1	Q2	Q3	Q4	Q1e	Q2e	Q3e	Q4e		2023	2024	2025e	2026e	2027e		
Svedbergs	113	113	102	76	102	106	107	81	107		480	393	401	420	441		
Macro Design	44	42	44	35	45	44	45	36	46		163	165	172	179	186		
Cassoe	23	23	25	19	21	22	23	19	22		88	87	87	90	93		
Roper Rhodes	250	289	285	289	275	310	298	303	283		1,062	1,138	1,193	1,236	1,280		
Thebalux	30	105	107	94	95	109	110	96	98		30	401	413	430	449		
Group	460	572	562	512	537	592	583	535	556		1,824	2,184	2,265	2,354	2,449		
Adj EBITA	2024					2025											
SEKm	Q4	Q1	Q2	Q3	Q4	Q1e	Q2e	Q3e	Q4e		2023	2024	2025e	2026e	2027e		
Svedbergs	8	8	1	1	6	4	4	4	7		58	17	19	24	31		
Macro Design	4	4	4	3	5	5	5	3	5		12	16	18	19	20		
Cassoe	5	4	5	3	4	4	5	4	4		18	17	17	17	18		
Roper Rhodes	52	49	49	55	60	57	55	61	60		177	214	233	246	255		
Thebalux	1	26	28	18	17	27	28	19	18		1	89	93	98	102		
Other	-11	-8	-12	-10	-11	-8	-12	-10	-11		-26	-40	-40	-40	-40		
Group	59	84	76	71	81	89	86	80	83		240	312	338	363	385		
Adj EBITA margin	2024					2025											
	Q4	Q1	Q2	Q3	Q4	Q1e	Q2e	Q3e	Q4e		2023	2024	2025e	2026e	2027e		
Svedbergs	7.1%	7.2%	1.3%	1.7%	5.8%	3.5%	4.0%	5.0%	6.1%		12.1%	4.2%	4.6%	5.8%	7.0%		
Macro Design	8.9%	9.7%	9.4%	8.1%	11.6%	10.2%	10.2%	8.3%	11.7%		7.6%	9.8%	10.2%	10.6%	11.0%		
Cassoe	20.5%	19.5%	20.3%	18.3%	17.9%	19.5%	20.5%	18.3%	17.7%		20.2%	19.1%	19.0%	19.1%	19.1%		
Roper Rhodes	20.9%	17.0%	17.2%	19.1%	21.9%	18.5%	18.5%	20.0%	21.2%		16.6%	18.8%	19.5%	19.9%	19.9%		
Thebalux	3.4%	24.8%	26.1%	19.5%	18.0%	25.0%	26.0%	19.5%	18.3%		3.4%	22.3%	22.4%	22.7%	22.8%		
Group	12.9%	14.6%	13.5%	13.9%	15.1%	15.0%	14.7%	15.0%	14.9%		13.2%	14.3%	14.9%	15.4%	15.7%		

Source: Company data, Carnegie Research

Financial statements

Profit & loss (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Sales	622	609	649	869	1,833	1,824	2,184	2,265	2,354	2,449
COGS	-363	-351	-375	-502	-1,076	-1,028	-1,188	-1,218	-1,253	-1,295
Gross profit	260	258	274	366	757	796	996	1,048	1,102	1,154
Other income & costs	-182	-177	-184	-240	-467	-523	-622	-644	-669	-696
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
EBITDA	77	80	90	127	290	273	374	403	432	458
Depreciation PPE	-10	-11	-10	-11	-15	-16	-19	-20	-21	-22
Depreciation lease assets	-2	-3	-3	-5	-19	-23	-31	-32	-33	-34
Amortisation development costs	0	0	0	0	0	0	0	0	0	0
Amortisation other intangibles	-9	-9	-9	-10	-12	-12	-13	-14	-15	-16
Impairments / writedowns	0	0	0	0	0	0	0	0	0	0
EBITA	56	58	68	101	244	222	312	338	363	385
Amortization acquisition related	-1	-2	-2	-6	-9	-11	-16	-16	-16	-16
Impairment acquisition related	0	0	0	0	0	0	0	0	0	0
EBIT	55	56	66	95	234	210	296	322	348	370
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
Net financial items	-3	-3	-4	-15	-28	-51	-67	-51	-43	-37
of which interest income/expenses	-3	-3	-4	-15	-28	-51	-67	-51	-43	-37
of which interest on lease liabilities	0	0	0	0	0	0	0	0	0	0
of which other items	0	0	0	0	0	0	0	0	0	0
Pre-tax profit	51	53	62	80	206	160	229	271	304	333
Taxes	-11	-12	-14	-21	-40	-41	-61	-70	-79	-87
Post-tax minorities interest	0	0	0	0	0	0	0	0	0	0
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Net profit	41	41	48	59	166	119	168	201	225	247
Adjusted EBITDA	79	80	100	146	298	291	375	403	432	458
Adjusted EBITA	58	58	78	119	251	240	312	338	363	385
Adjusted EBIT	57	56	76	114	242	229	297	322	348	370
Adjusted net profit	44	43	58	78	181	144	184	216	241	262
Sales growth Y/Y	-2.7%	-2.1%	6.6%	33.8%	111.0%	-0.5%	19.7%	3.7%	3.9%	4.0%
EBITDA growth Y/Y	-7.3%	3.7%	12.4%	41.0%	128.7%	-6.0%	37.2%	7.8%	7.2%	5.9%
EBITA growth Y/Y	-12.8%	3.7%	16.9%	48.3%	142.1%	-9.1%	40.7%	8.3%	7.6%	6.1%
EBIT growth Y/Y	-13.2%	2.7%	17.9%	43.7%	146.5%	-10.2%	40.8%	8.7%	8.0%	6.3%
EBITDA margin	12.4%	13.2%	13.9%	14.6%	15.8%	15.0%	17.1%	17.8%	18.4%	18.7%
EBITA margin	9.0%	9.5%	10.5%	11.6%	13.3%	12.2%	14.3%	14.9%	15.4%	15.7%
EBIT margin	8.8%	9.2%	10.2%	10.9%	12.8%	11.5%	13.6%	14.2%	14.8%	15.1%
Tax rate	20.6%	22.4%	22.4%	26.1%	19.7%	25.6%	26.6%	26.0%	26.0%	26.0%
Cash flow (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
EBITDA	77	80	90	127	290	273	374	403	432	458
Paid taxes	-16	0	-12	0	-30	-49	-61	-70	-79	-87
Change in NWC	-2	-17	18	-5	0	13	-76	-18	-19	-21
Non cash adjustments	-2	0	2	-10	8	10	18	0	0	0
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Total operating activities	58	63	98	112	269	246	256	315	334	351
Capex tangible assets	-11	-21	-18	-6	-14	-12	-52	-14	-14	-15
Capitalised development costs	-6	-5	-9	-7	-9	-11	-9	-14	-14	-15
Capex - other intangible assets	-1	0	0	-1	-7	-3	0	0	0	0
Acquisitions/divestments	0	0	-57	-788	-149	-477	0	0	0	0
Other non-cash adjustments	0	0	0	0	0	0	1	0	0	0
Total investing activities	-18	-26	-84	-803	-179	-502	-60	-27	-28	-29
Net financial items	-3	-3	-4	-15	-28	-51	-67	-51	-43	-37
Lease payments	0	-2	0	0	-17	-23	-23	-32	-33	-34
Dividend paid and received	-48	-26	0	-26	0	-53	-53	-93	-106	-123
Share issues & buybacks	0	0	0	0	480	0	391	0	0	0
Change in bank debt	15	8	12	992	-655	407	-445	-148	-123	-127
Other cash flow items	1	1	1	2	0	0	0	0	0	0
Total financing activities	-35	-22	8	952	-222	280	-197	-324	-306	-321
Operating cash flow	58	63	98	112	269	246	256	315	334	351
Free cash flow	37	32	67	82	193	147	105	205	229	250
Net cash flow	5	15	22	261	-131	24	-1	-36	0	0
Change in net IB debt	-10	7	7	-736	534	-390	456	113	123	127
Capex / Sales	1.8%	3.4%	2.8%	0.7%	0.7%	0.6%	2.4%	0.6%	0.6%	0.6%
NWC / Sales	22.6%	24.6%	23.2%	23.5%	17.1%	21.2%	20.5%	21.6%	21.5%	21.5%

Source: Carnegie Research & company data

Financial statements, cont.

Balance sheet (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Acquired intangible assets	114	114	162	485	614	838	886	886	886	886
Other fixed intangible assets	46	46	98	503	388	543	559	543	526	509
Capitalised development	0	0	0	0	0	0	0	0	0	0
Tangible assets	70	75	71	282	289	379	428	421	414	407
Lease assets	0	9	9	40	28	82	82	82	82	82
Other IB assets (1)	0	0	0	0	0	0	0	0	0	0
Other non-IB assets	0	0	0	0	2	3	5	5	5	5
Fixed assets	231	245	341	1,311	1,320	1,845	1,959	1,937	1,913	1,889
Inventories (2)	118	134	130	342	444	499	559	579	602	626
Receivables (2)	126	120	138	322	291	296	295	306	318	331
Prepaid exp. & other NWC items (2)	5	5	7	66	16	44	35	36	37	38
IB current assets (1)	0	0	0	0	0	0	0	0	0	0
Other current assets	7	0	0	2	19	21	38	38	38	38
Cash & cash equivalents (1)	21	36	58	320	200	217	236	200	200	200
Current assets	277	296	334	1,051	971	1,076	1,162	1,159	1,195	1,233
Total assets	508	541	674	2,362	2,291	2,921	3,121	3,096	3,108	3,122
Shareholders' equity	163	179	227	267	935	979	1,530	1,637	1,757	1,880
Minorities	0	0	0	0	0	0	0	0	0	0
Other equity	0	0	0	0	0	0	0	0	0	0
Total equity	163	179	227	267	935	979	1,530	1,637	1,757	1,880
Deferred tax	17	21	36	173	132	174	194	194	194	194
LT IB debt (1)	131	132	132	528	563	490	648	500	376	249
Other IB provisions (1)	0	0	0	0	0	0	0	0	0	0
Lease liabilities	0	10	9	39	29	83	83	83	83	83
Other non-IB liabilities	0	0	25	163	164	187	6	6	6	6
LT liabilities	148	162	202	903	887	934	930	782	658	531
ST IB debt (1)	86	93	105	718	61	576	246	246	246	246
Payables (2)	43	37	39	102	113	161	183	189	197	205
Accrued exp. & other NWC items (2)	65	64	94	362	279	263	226	234	244	253
Other ST non-IB liabilities	3	5	8	10	16	9	8	8	8	8
Liabilities - assets held for sale	0	0	0	0	0	0	0	0	0	0
Current liabilities	197	199	245	1,192	468	1,008	662	677	693	711
Total equity and liabilities	508	541	674	2,362	2,291	2,921	3,121	3,096	3,108	3,122
Net IB debt (=1)	195	198	188	966	453	931	740	628	504	377
Net working capital (NWC) (=2)	142	159	143	265	360	414	480	497	517	537
Capital employed (CE)	397	434	509	1,725	1,720	2,301	2,699	2,659	2,655	2,651
Capital invested (CI)	372	404	484	1,576	1,678	2,256	2,434	2,429	2,425	2,422
Equity / Total assets	32%	33%	34%	11%	41%	34%	49%	53%	57%	60%
Net IB debt / EBITDA	2.5	2.5	2.1	7.6	1.6	3.4	2.0	1.6	1.2	0.8
Per share data (SEK)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Adj. no. of shares in issue YE (m)	21.12	21.15	21.16	26.00	33.77	35.32	51.67	52.98	52.98	52.98
Diluted no. of Shares YE (m)	21.12	21.15	21.16	26.00	33.77	35.32	52.98	52.98	52.98	52.98
EPS	1.93	1.96	2.28	2.26	4.90	3.37	3.25	3.79	4.25	4.66
EPS adj.	2.07	2.05	2.72	3.01	5.35	4.07	3.56	4.08	4.55	4.95
CEPS	2.99	2.98	3.40	3.49	6.04	4.48	4.33	4.72	5.23	5.67
DPS	2.25	0.00	1.25	0.00	1.50	1.00	1.50	1.75	2.00	2.33
BVPS	7.71	8.46	10.7	10.3	27.7	27.7	28.9	30.9	33.2	35.5
Performance measures	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
ROE	24.6%	24.3%	23.7%	23.8%	27.5%	12.4%	13.4%	12.7%	13.3%	13.6%
Adj. ROCE pre-tax	15.7%	15.1%	17.3%	11.3%	15.4%	12.7%	12.7%	12.7%	13.8%	14.6%
Adj. ROIC after-tax	12.4%	11.6%	13.6%	8.6%	12.4%	9.1%	9.8%	10.3%	11.1%	11.8%
Valuation	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
FCF yield	1.5%	1.4%	2.8%	3.4%	8.1%	6.2%	4.4%	8.6%	9.6%	10.5%
Dividend yield YE	14.3%	0.0%	5.1%	0.0%	6.8%	3.2%	3.6%	3.9%	4.5%	5.2%
Dividend payout ratio	116.9%	0.0%	54.9%	0.0%	30.6%	29.7%	46.1%	46.2%	47.0%	50.0%
Dividend + buy backs yield YE	8.0%	0.0%	5.1%	0.0%	7.1%	4.8%	4.2%	4.5%	5.2%	5.6%
EV/Sales YE	0.85	0.89	1.09	2.96	0.66	1.11	1.34	1.33	1.22	1.13
EV/EBITDA YE	6.8	6.8	7.9	20.3	4.1	7.4	7.8	7.5	6.7	6.0
EV/EBITA YE	9.4	9.4	10.4	25.5	4.9	9.2	9.4	8.9	7.9	7.2
EV/EBITA adj. YE	9.1	9.4	9.1	21.5	4.8	8.5	9.4	8.9	7.9	7.2
EV/EBIT YE	9.6	9.7	10.7	27.0	5.1	9.7	9.9	9.3	8.3	7.5
P/E YE	8.2	8.3	10.8	27.3	4.5	9.3	12.7	11.9	10.6	9.6
P/E adj. YE	7.6	8.0	9.1	20.5	4.1	7.7	11.6	11.0	9.9	9.1
P/BV YE	2.04	1.94	2.29	6.02	0.80	1.13	1.44	1.45	1.35	1.27
Share price YE (SEK)	15.7	16.4	24.6	61.8	22.2	31.2	41.5	44.9		

Source: Carnegie Research & company data

Disclosures and disclaimers

Carnegie Investment Bank AB

Carnegie Investment Bank AB (publ.) is a leading investment bank with a Nordic focus. The Carnegie group of companies, together "Carnegie", generates added value for institutions, companies and private clients in the areas of trade in securities, investment banking and private banking. Carnegie has approximately 600 employees, located in offices in six countries

Valuation, methodology, and assumptions

Commissioned research reports include the analyst's assessment of a fair value range over the coming six to 12 months based on various fundamental valuation methods. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E ratio and EV/EBIT multiples, relative to industry peers. For companies where it is appropriate, a fair value range can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Fair value ranges represent the assessment of the analyst(s) at the time of writing

Frequency of update

Carnegie's research analysis consists of case-based analyses, which implies that the frequency of the analytical report may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

Analyst certification

The research analyst or analysts responsible for the content of this commissioned research report certify that, notwithstanding the existence of any potential conflicts of interests referred to herein, the views expressed in this commissioned research report accurately reflect the research analyst's personal views about the companies and securities covered. It is further certified that the research analyst has not been, nor is or will be, receiving direct or indirect compensation related to the specific ratings or views contained in this commissioned research report.

Potential conflicts of interest

Carnegie, or its subsidiaries, may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this report. Any such publicly announced business activity, during the past 12 months, will be referred to in this commissioned research report. A set of rules handling conflicts of interest is implemented in the Carnegie Group. Investment Banking and other business departments in Carnegie are surrounded by information barriers to restrict the flows of sensitive information. Persons outside such barriers may gain access to sensitive information only after having observed applicable procedures. The remuneration of persons involved in preparing this commissioned research report is not tied to investment banking transactions performed by Carnegie or a legal person within the same group.

Confidential and non-public information regarding Carnegie and its clients, business activities and other circumstances that could affect the market value of a security ("sensitive information") is kept strictly confidential and may never be used in an undue manner.

Internal guidelines are implemented in order to ensure the integrity and independence of research analysts. In accordance with the guidelines the research department is separated from the Investment Banking department and there are no reporting lines between the research department and Investment Banking. The guidelines also include rules regarding, but not limited to, the following issues; contacts with covered companies, prohibition against offering favourable recommendations, personal involvement in covered companies, participation in investment banking activities, supervision and review of research reports, analyst reporting lines and analyst remuneration.

Other material conflicts of interest

This report was commissioned and sponsored by the issuer (issuer-paid research).

Distribution restrictions

This commissioned research report is intended only for distribution to professional investors. Such investors are expected to make their own investment decisions without undue reliance on this commissioned research report. This commissioned research report does not have regard to the specific investment objectives, financial situation or particular needs of any specific person who may receive it. Investors should seek financial advice regarding the appropriateness of investing in any securities discussed in this commissioned research report and should understand that statements regarding future prospects may not be realized. Past performance is not necessarily a guide to future performance. Carnegie and its subsidiaries accept no liability whatsoever for any direct or consequential loss, including, without limitation, any loss of profits arising from the use of this commissioned research report or its contents. This commissioned research report may not be reproduced, distributed or published by any recipient for any purpose. The document may not be distributed to persons that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.

This commissioned research report is distributed in Sweden by Carnegie Investment Bank AB. Carnegie Investment Bank AB is a bank incorporated in Sweden with limited liability which is authorised and regulated by the Swedish Financial Supervisory Authority (Finansinspektionen). In Finland this commissioned research report is issued by Carnegie Investment Bank AB, Finland Branch. The Finland branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Finnish Financial Supervisory Authority (Finanssivalvonta). In Norway this commissioned research report is issued by Carnegie AS, a wholly-owned subsidiary of Carnegie Investment Bank AB. Carnegie AS is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet). In Denmark this commissioned research report is issued by Carnegie Investment Bank AB, Denmark Branch. The Denmark branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Danish Financial Supervisory Authority (Finanstilsynet).

This commissioned research report is distributed in the US by Carnegie, Inc., a US-registered broker-dealer and a member of FINRA and SIPC. Carnegie's research analysts located outside of the US are employed by non-US affiliates of Carnegie Inc. ("non-US affiliates") that are not subject to FINRA regulations. Generally, Carnegie research analysts are not registered with or qualified as research analysts with FINRA, and therefore are not subject to FINRA rule 2241 restrictions intended to prevent conflicts of interest by, among other things, prohibiting certain compensation practices, restricting trading by analysts and restricting communications with the companies that are the subject of the research report. Research reports distributed in the U.S. are intended solely for major US institutional investors and US institutional investors as defined under Rule 15a-6 of the Securities Exchange Act of 1934. This commissioned research report is provided for informational purposes only and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy any securities. Reports regarding equity products are prepared by non-US affiliates of and distributed in the United States by Carnegie Inc. under Rule 15a-6(a)(3). When distributed by Carnegie Inc, Carnegie Inc. takes responsibility for the commissioned research report. Any US person who wishes to effect transactions based on this commissioned research report should contact Carnegie Inc. Investors in the US should be aware that investing in non-US securities entails certain risks. The securities of non-US issuers may not be registered with, or be subject to, the current information reporting and audit standards of the US Securities and Exchange Commission.

This commissioned research report has been issued in the UK by Carnegie UK which is the UK Branch of Carnegie Investment Bank AB. Carnegie UK is authorised and regulated by the Financial Conduct Authority (FCA).

Research Disclaimer

This commissioned research report is provided solely for information. It does not constitute or form part of, and shall under no circumstances be considered as an offer to sell or a solicitation of an offer to purchase or sell any relevant financial instrument.

This commissioned research report has been requested and paid for by the issuer and should therefore be considered a marketing communication (i.e. not investment research). Payment for the report has been agreed in advance on a non-recourse basis. As commissioned research, this material can be considered an acceptable minor non-monetary benefit under MiFID II. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, it is still subject to a prohibition on dealing ahead of the dissemination of the report.

Carnegie Investment Bank AB is responsible for the preparation of this commissioned research report in Sweden, Finland, Denmark, and the UK. Carnegie AS is responsible for the preparation of this commissioned research report in Norway. Carnegie Inc. is responsible for this research report in the US.

The information in this commissioned research report was obtained from various sources. While all reasonable care has been taken to ensure that the information is true and not misleading, Carnegie gives no representation or warranty, express or implied, about its accuracy or completeness. Carnegie, its subsidiaries and any of their officers or directors may have a position, or otherwise be interested in, transactions in securities that are directly or indirectly the subject of this commissioned research report. Any significant financial interests held by the analyst, Carnegie or a legal person in the same group in relation to the issuer will be referred to in the company-specific disclosures.

Company specific disclosures

The following disclosures relate to relationships between Carnegie Investment Bank AB (with its subsidiaries, "Carnegie") and the issuer or an affiliate.

Parts of this commissioned research report may have been submitted to the issuer prior to its publication.

Copyright © 2025 Carnegie



Commissioned Research sponsored by Svedbergs Group

12 February 2025

Carnegie Investment Bank AB

Regeringsgatan 56
SE-103 38 Stockholm
Tel +46 8 5886 88 00 Fax +46 8 5886 88 95
www.carnegie.se
A member of the Stockholm Stock Exchange

Carnegie Investment Bank, Denmark Branch

Overgaden neden Vandet 9B PO Box 1935
DK-1414 Copenhagen K
Tel +45 32 88 02 00 Fax +45 32 96 10 22
www.carnegie.dk
A member of the Copenhagen Stock Exchange

Carnegie Investment Bank AB, Finland Branch

Eteläesplanadi 2 PO Box 36
FI-00131 Helsinki
Tel +358 9 618 71 230 Fax +358 9 618 71 720
www.carnegie.fi
A member of the Helsinki Stock Exchange

Carnegie AS

Fjordalleen 16, 5th Floor PO Box 684,
Sentrum NO-0106 Oslo
Tel +47 22 00 93 00 Fax +47 22 00 94 00
www.carnegie.no
A member of the Oslo Stock Exchange

Carnegie, Inc.

20 West 55th St. ,
New York N.Y. 10019
Tel +1 212 262 5800 Fax +1 212 265 3946
www.carnegiegroup.com
Member FINRA / SIPC

Carnegie Investment Bank AB, UK Branch

Finwell House, 26 Finsbury Square
London EC2A 1DS
Tel +44 20 7216 4000 Fax +44 20 7417 9426
www.carnegie.co.uk
Regulated by the FCA in the conduct of Designated
Investment Business in the UK